Abstract: Breastfeeding is natural and the optimal basis of infant nutrition and development, with many benefits for maternal health. Human milk is a dynamic fluid fulfilling an infant’s specific nutritional requirements and guiding the growth, developmental, and physiological processes of the infant. Human milk is considered unique in composition, and it is influenced by several factors, such as maternal diet and health, body composition, and geographic region. Human milk stands as a model for infant formula providing nutritional solutions for infants not able to receive enough mother’s milk. Infant formulas aim to mimic the composition and functionality of human milk by providing ingredients reflecting those of the latest human milk insights, such as oligosaccharides, bacteria, and bacterial metabolites. The objective of this narrative review is to discuss the most recent developments in infant formula with a special focus on human milk oligosaccharides and postbiotics.

Keywords: human milk oligosaccharides; probiotics; prebiotics; synbiotics; postbiotics; 2′-fucosyllactose (2′-FL); lacto-N-neotetraose (LNnT); 3′-galactosyllactose (3′-GL); breastfeeding; infant formula

1. Introduction

Nutrition in early infancy and childhood can significantly impact growth and development as well as immediate and later health [1]. The World Health Organization recommends exclusive breastfeeding for the first six months of life, followed by continued breastfeeding with appropriate complementary foods for up to two years or beyond [2]. Breastfeeding and/or nutritional intervention during early life can help prevent both infectious and non-communicable disease risk during childhood and into adulthood [1].

A healthy gut development is of major importance during infancy. It contributes to growth and development by ensuring digestion and absorption of nutrients and fluids. The gut is also key in the development of immunity insofar as it maintains a barrier against infectious agents and interacts directly with the immune system to induce mucosal and systemic tolerance, which prevents of allergy. Furthermore, the gut provides signals to the brain to maintain a healthy state [3].

One of the major factors enabling proper gut function and development is a balanced gut microbiota [4]. Several prenatal and perinatal factors including mode of delivery, use of antibiotics, diet, and other environmental factors, including geographic region, may influence the microbial colonisation
of the infant and in turn the maturation of the immune system, as reviewed elsewhere [5]. Hence, it is generally agreed that the gut microbiota of the healthy, full-term, vaginally delivered and breastfed infant constitutes the gold standard for a favourable microbial composition in early life [6]. Since human milk contributes remarkably to the development of a balanced gut microbiota—amongst many other health benefits—it is essential for infant formula to be as close to human milk as possible, providing bioactives targeting gut and immune health [7].

Two human milk oligosaccharides (HMOs), 2′-fucosyllactose (2′FL) and lacto-N-neotetraose (LNNt), are recent examples of optional ingredients being added to infant formula [8–11]. However, little attention has yet been given to 3′-galactosyllactose (3′-GL), which is an HMO present in human milk that may also naturally occur in fermented infant formula derived by milk fermentation [12,13]. This narrative review will focus on these most recent developments in infant formula as examples of ‘biotics’ aiming to resemble human milk functions in infant formula.

2. Oligosaccharides, Bacteria, and Microbial Metabolites in Human Milk

Human milk contains many bioactive compounds such as oligosaccharides, immune cells, and varying levels of bacteria and their metabolites. They play an important role in the development of a healthy gut by supporting a favourable intestinal microbiota and in the development of the infant’s immune system [14–18].

2.1. Human Milk Oligosaccharides (HMOs)

HMOs are pools of complex carbohydrates, the third most abundant component of human milk, and one example of naturally occurring ‘prebiotics’ [19]. Although originally characterised as HMOs, they are also present in the amniotic fluid, and thus the foetus is already exposed to HMOs prior to birth when ingesting the amniotic fluid [20–23].

The quantity of HMOs in mature human milk is approximately 12–15 g/L as reported elsewhere [24,25]. There are more than 200 structurally different HMOs working together to deliver a combined beneficial effect, of which today more than 160 (neutral and acidic) types have been characterized in detail [26].

Most HMOs escape digestion in the small intestine [16] and progress to the colon acting as decoy molecules binding pathogens and getting metabolised as ‘food’ for the commensal gut bacteria [27], such as bifidobacteria and lactic acid bacteria, allowing such bacterial populations to become more abundant [28]. Besides their prebiotic effect, HMOs also have direct effects on immune cells [29–32], block the routes of infections [30,33], provide building blocks for the brain [34], and stimulate intestine barrier functions, as published elsewhere [35].

HMOs are synthesised in the mammary gland by the prolongation of lactose with monosaccharides forming non-digestible trisaccharides (DP3) (degree of polymerisation, which is the amount of monosaccharide building blocks) or tetrasaccharides (DP4). The addition of sialic acids leads to two different sialyllactoses (SL), 3′-SL and 6′-SL (DP3), and the addition of fucose leads to two different fucosyllactoses (FL), 2′-FL and 3-FL (DP3), as well as difucosyllactose (DP4) [25,36,37] (Figure 1).

HMOs also include galactosyllactoses (GLs), which appear in the form of several structurally distinct isomers and only differing in the glycosidic linkage of the terminal galactose added to lactose, leading to 3′-GL, 4′-GL, and 6′-GL (DP3) [38,39] (Figure 2). Those HMOs can also be derived from lactose by the enzymatic activity of bacterial β-galactosidases, which splits lactose to glucose and galactose and catalyses the transgalactosylation of lactose to produce GLs [40–43]. Using an adapted approach of a recently published targeted liquid chromatography-tandem mass spectrometry method for HMOs, native GL-isomers like 3′-GL could be directly detected in human milk samples from various stages of lactation. The abundance of 3′-GL appeared to be relatively stable between colostrum and mature milks, whereas 6′-GL declined over time [44]. In general, HMO concentrations decline over time from colostrum to mature milk [45], including GLs [39,46]. Thurl et al. also found a slight decrease in HMOs within the first 90 days of lactation [47]; however, this might be partly compensated for by more volume of human milk being consumed by infants in the respective longitudinal setting.
Nutrients 2020, 12, 1952

Figure 1. Chemical structure of neutral and acidic human milk oligosaccharides (HMOs) (adapted from Thurl et al. [25], Newburg et al. [38], and Urashima et al. [26]).

Larger HMO structures are derived by adding galactose and N-acetylglucosamine as disaccharide building blocks, which leads to tetrasaccharides (DP4), Lacto-N-tetraose (LNT), and Lacto-N-neotetraose (LNNnT). Those tetrasaccharides can be further extended by those disaccharide units (DP6, DP8, etc.) and in addition decorated with further single or multiple fucose residues, leading to large neutral HMOs with a molecular size up to 8 kDa [49] and/or single or multiple sialic acid residues, leading to large acidic HMOs with a molecular size up to 3.6 kDa [50].

Size exclusion chromatography, which was further used to describe the complexity of short- and long-chain HMOs, demonstrated a molecular size distribution of short-chain and long-chain HMOs in a ratio of 9:1 [49]. Long-chain HMOs are less easily fermented by the gut microbiota, whereas short-chain HMOs are more active in the proximal parts of the gut [26], ensuring that potential substrates are available for the gut microbiota through the gastrointestinal tract, as shown for homo-polymeric fructans [51].
Although the long-chain HMOs are less abundant, they may exert a relevant bioactivity, which leads to the conclusion that abundance cannot automatically explain the biological importance of a molecule.

2.2. Bacteria in Human Milk

Human milk is also an important source of beneficial bacteria (naturally occurring ‘probiotics’) that help colonise the infant gut and contribute to the composition of a favourable gut microbiota, including *Bifidobacterium* spp. and *Lactobacillus* spp. [52,53], with genus *Bifidobacterium* dominating the gut microbiota of a vaginally delivered infant [54,55]. Bacteria in human milk are anticipated to be bioactive components regulating the development of an infant’s immune system and attenuating inflammation processes [56]. In general, the microbiome of human milk is a recent field of research, as explored elsewhere [53,56–59].

The total number of bacteria in human milk significantly differs according to detection methods. It has been estimated that human milk contains median values between $10^3$ and $10^6$ bacteria per millilitre [60–62]. The difference in number caused by different detection methods could be due to the fact that in molecular-based methods, DNA from non-viable bacteria and extracellular DNA can also be amplified, suggesting that not only live bacteria but significant amounts of non-viable bacteria coexist in human milk [60].

2.3. Microbial Metabolites in Human Milk

Besides bacteria, their metabolites (e.g., butyrate and other short-chain fatty acids (SCFAs), peptides, oligosaccharides) may also naturally pass into human milk, and this can be detected through metabolomics research using nuclear magnetic resonance spectroscopy [63,64]. Most recently these metabolites have gained more research attention that is focused on their possible role in shaping the growth and development of the infant. A widely accepted definition still needs to be agreed on, but in general, they may also be referred to as ‘natural postbiotics’ (comprising both inactivated bacterial cells and metabolites) and are anticipated to stimulate both healthy gut microbiota composition and function as well as immune functioning and development [60,64,65].

3. The ‘Biotic’ Family: Resembling Human Milk Benefits in Infant Formula

There is increasing research on nutritional postnatal interventions using probiotics, prebiotics, synbiotics, and the so-called postbiotics to promote the establishment of a beneficial microbiota and to have a positive impact on neonatal health (Figure 3). Whereas infant formulas can only provide static selections of these substances, the amount and composition are highly dynamic and individual in human milk [47,66,67]. This may be illustrated by the diversity of oligosaccharide structures in human milk, which has been shown to vary among women according to genetic factors, geographical regions, stages of lactation, and, potentially, maternal probiotic supplementation during the late stages of pregnancy [45,47,68]. For example, in women with the active gene for fucosyltransferase 2 (FUT2, secretors), 2′-FL is by far the most abundant HMO, with a mean concentration of 2.7 g/L, and constitutes nearly 24% of all HMOs [25]. However, in the milk of women without the active gene for FUT2 (non-secretors), who make up 21% of all women in larger parts of the world, 2′-FL was not found [24,25,67].

According to a recent consensus definition, probiotics are live microorganisms that confer a health benefit on the host when administered in adequate amounts [69], whereas prebiotics are defined as substrates that are selectively utilised by host microorganisms conferring a health benefit [70]. An official definition of synbiotics, which are a combination of both pro- and prebiotics [71], will soon be published by the International Scientific Association for Probiotics and Prebiotics (ISAPP). In contrast to pre- and probiotics, an official aligned global definition of postbiotics is still pending and will be discussed later in this paper.
3.1. Probiotics

Most probiotic-containing infant formula comprise *Bifidobacterium* spp. and/or lactic acid bacteria such as *Lactobacillus* spp., which are generally regarded as safe for food use in the European Union based on the QPS-list (Qualitative Presumption of Safety) of bacteria. In the United States, a non-mandatory system of safety evaluation is in place, provided by the U.S. Food & Drug Administration (FDA). On request, it evaluates safety assessment filings of specific probiotic strains to be included in the so-called GRAS (Generally Recognized as Safe) Notice Inventory, which is continuously updated [73].

There are data on specific probiotics in infant formula accompanied by a large diversity in study outcomes [74]. However, these health benefits are very strain and disease specific. For example, for preterm infants, the Committee on Nutrition of the European Society for Paediatric Gastroenterology and Nutrition (ESPGHAN) and the ESPGHAN Working Group for Probiotics and Prebiotics conditionally recommended the use of *Lactobacillus* GG (LGG) ATCC 53103 (at a daily dose ranging from 1 × 10⁹ CFU to 6 × 10⁹ CFU) and the combination of *B. infantis* Bb-02, *B. lactis* Bb-12, and *Str. thermophilus* TH-4 (at a daily dose of 3.0 to 3.5 × 10⁹ CFU of each strain) as it might reduce necrotizing enterocolitis (NEC) stage 2 or 3 in preterm infants (low certainty of evidence), but mortality and sepsis did not show any clear direction in effect size. However, no recommendation could be made in either direction regarding the use of *L. reuteri* DSM 17938 and the combination of *B. bifidum* NCDO 1453 (currently reclassified as *B. longum*) with *Lactobacillus* NCDO 1748 (ATCC 4356, LA37, or NCIMB 30316) in preterm infants to reduce the risk of mortality, NEC stage 2 or 3, or sepsis (very low certainty of evidence) [75]. For term born infants, in a review from 2011, the ESPGHAN Committee on Nutrition did not recommend the routine use of probiotic- and/or prebiotic-supplemented infant formulas, identifying further need for well-designed and carefully conducted randomised controlled trials [74].

3.2. Prebiotics

Because of their stability, low risk of adverse effects, ease of administration, and potential for influencing the composition and function of the microbiota in the gut and beyond, the clinical applications of prebiotics are expanding [76].

In last decades, different prebiotic mixtures of galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) have been studied. Globally the most studied prebiotic mixture of oligosaccharides in infant formula consists of short-chain (sc) GOS and long-chain (lc) FOS, scGOS/lcFOS (9:1). The mix is in the range of HMOs close to human milk in quantity (8g/L) and diversity (more than 100 different structures of short- and long-chain types in a ratio of 9:1). Although this prebiotic mixture approaches the molecule size distribution of short- and long-chain oligosaccharides in human milk, it is not structurally similar to HMOs [77]. Clinical research on scGOS/lcFOS (9:1) showed benefits linked to modulation of the gut microbiota and the immune system, reduced incidence of infections, and stool
softening [76,78,79]. This prebiotic mixture has been recognised as a prebiotic by ISAPP [70], and it may be added to infant formula and follow-on formula according to the Commission Delegated Regulation (EU) 2016/127 [80]. However, to date, there are no health claims granted by the European Food Safety Authority (EFSA) for the application of any oligosaccharides in infant formula.

In addition to prebiotics based on GOS and/or FOS, infant formulas have recently been supplemented with specific technically derived HMOs (e.g., 2′-FL and LNNnT), which have been anticipated as candidate prebiotics [70] (see Section 3.3).

### 3.3. Specific HMOs Added to and/or Present in Infant Formula

Recent research highlights the variety of HMOs in human milk, underlining the importance of scientific assessment of the role of both minor and major oligosaccharides in promoting infant health before adding it to infant formula.

Technically, only 2′-FL and LNNnT are currently commercially available for addition to infant formula as purified ingredients [81]. The technology used for obtaining these is the coupling of bacterial homogenates or the utilisation of E. coli as a microbial cell factory (see Table 1). Other technologies are available but, currently, only used for analytical and research purposes. While 2′-FL and LNNnT are obtained by chemical synthesis, 3′-GL occurs as a bacterial by-product during milk fermentation [12,13]. Besides these three examples, further HMOs are in the pipeline for application in infant formula [81].

Table 1. Current technologies for obtaining commercially available HMOs for application in infant formula (data on 2′-FL and LNNnT are adapted from Bych et al. [81], data on 3′-GL from Rodriguez-Herrera et al. [12]).

| HMO | Technology | Application | Ref |
|-----|------------|-------------|-----|
| 2′-FL and LNNnT | Isolation from human milk | For structural identification and fundamental research applications only | [40,82–84] |
| | Chemo-enzymatic synthesis using recombinantly expressed glycosyltransferases matched with nucleotide-activated donor substrates and acceptors | For generating libraries of asymmetrical multi-antennary HMOs for research purposes only | [85] |
| | Chemical synthesis from L-fucose, D-galactose, N-acetyl-D-glucosamine, and D-lactose, respectively | Prohibitively expensive for large-scale nutrition applications due to complexity, number of reaction steps, limited availability, and high cost of raw materials | [86–89] |
| | Coupling of the bacterial homogenates of two or more recombinant microbial cells overexpressing genes for HMO synthesis | For the industrial manufacturing of LNNnT and fucosylated oligosaccharides | [90,91] |
| | Microbial fermentation of engineered E. coli strains for fucosylation reaction (complete removal of the strain and all other non-desired biomolecules after fermentation) | Used for both research and viable commercial production with high titers of 2′-FL and LNNnT | [92] |
| 3′-GL | Milk fermentation process using Bifidobacterium breve C50 and Streptococcus thermophilus 065 and providing 3′-GL as a metabolic by-product at levels of ~250 µg/mL | Proprietary fermentation process (Lactofidus™) for large-scale production of fermented infant formula | [12] |

### 3.3.1. HMOs 2′-FL and LNNnT

2′-FL and LNNnT have been anticipated as candidate prebiotics [70]. Although manufactured HMOs are structurally identical to their counterparts in human milk, regulatory approval is required
for novel foods by the European Union (Commission Implemented Regulation (EU) 2017/2470) [93]. The EFSA Scientific Panel on Nutrition recently assessed 2′-FL, difucosyllactose (DFL), LNnT, and LNT as safe for use in infant formula [94–96]. Furthermore, 2′-FL, DFL, LNnT, and LNT have been added to the GRAS-list derived from the FDA [97].

Preclinical research has shown that synthetic 2′-FL (with an identical structure as the 2′-FL found in human milk and often prepared from lactose) has prebiotic effects and may deliver functional benefits in infants. In preclinical trials, 2′-FL promoted the growth of specific bifidobacteria [98,99], blocked the growth of pathogens [100–102], and supported gut maturation and the stimulation of the gut intestinal barrier [103]. Furthermore, 2′-FL impacted neuronal dependent gut migrating motor complexes, suggesting beneficial effects on the central nervous system [104].

Infant formulas containing 2.4 g total oligosaccharides/L (control: scGOS only; experimental formulas: scGOS + 0.2 or 1.0 g 2′-FL/L) have been demonstrated to be safe in terms of normal growth and were well-tolerated in a prospective, randomised, a controlled growth and tolerance study with 189 healthy, singleton infants [9]. A post-hoc analysis of this study revealed that infants receiving 0.2 g/L 2′-FL had a significantly reduced incidence of respiratory infections as compared to the control group receiving scGOS alone. This effect was not seen in the group receiving 1.0 g/L 2′-FL [10]. A further analysis of the same study showed that infants who received the 2′-FL-containing formulas had significantly lower plasma inflammatory cytokines compared to infants who received the control formula, closely resembling the levels found in the breastfed reference group, potentially indicative of an anti-inflammatory effect [8].

A recently developed infant formula concept combines a prebiotic mixture of scGOS/lcFOS (9:1) and 2′-FL to further mimic the complex composition of HMO structures and their functional benefits. Data from the first in vivo pre-clinical investigations showed positive effects of this combination in a rotavirus model [105] and in a vaccination model [32,106].

LNnT has been assessed in vitro for function as a prebiotic inducing growth and metabolic activity in Bifidobacterium infantis [107]. As an ingredient, LNnT proved to be a stable and safe component of infant formula that was evaluated for its ability to reduce oropharyngeal colonisation with Streptococcus pneumoniae in children (6 months or older). Although colonisation was not reduced, LNnT proved to be well-tolerated at the tested concentration of 200 mg/L [107].

Infant formula supplemented with a combination of 2′-FL (1.0 g/L) and LNnT (0.5 g/L) was demonstrated to be safe and well-tolerated and to support age-appropriate growth in a multicentre, randomised, double-blind trial with 175 healthy infants, with weight gain as a primary study outcome. Secondary outcomes were also found including associations of lower parent-reported morbidity (particularly bronchitis) and medication use (antipyretics and antibiotics) in infants fed the supplemented formula compared to the control [11].

3.3.2. HMO 3′-GL

HMO 3′-GL is naturally present in human milk and was already isolated from human milk in 1988 [40]. Recently, a single chromatography run using an improved sample pre-treatment method and ultrahigh pressure liquid chromatography with fluorescence detection quantified 15 sialylated and neutral HMOs with high sensitivity, identifying 3′-GL and 6′-GL in colostrum, transitional, and mature human milk [108]. Human milk from mothers with preterm delivery revealed 3′-GL concentrations of 4–28.82 µg/mL (median 10.44) at 1 w postpartum, whereas concentrations ranged from 4–32.97 µg/mL (median 12.34) in colostrum and 4–20.73 µg/mL (median 4) at 8 w postpartum from mothers with term delivery [46]. Further human milk analyses of mothers with term delivery revealed 47–79 µg/mL of 3′-GL in colostrum [109], 5.08 ± 0.45 µg/mL (mean ± SD) in colostrum, and 4.84 ± 0.48 µg/mL (mean ± SD) at 100 d of lactation [39], and 0.5–39 µg/mL (median 4.6) in milk pooled until 21 d of lactation [38].

In pre-clinical studies, 3′-GL, 4′-GL, and 6′-GL prepared from colostrum individually accounted for specific immunomodulation of polyinosinic:polycytidylic acid-induced interleucin-8 levels in
an immature human intestine tested at a concentration of 200 µg/mL each [109]. Another study reported that a solution of 5 mg galactosyloligosaccharides/mL, which was synthesized from lactose and comprised of 14 % 3'-GL, 8 % 4'-GL, and 12 % 6'-GL, demonstrated ex vivo anti-inflammatory effects by attenuating the nuclear transcription factor κB inflammatory signalling in human intestinal epithelial cells [38]. In a model for intestinal barrier function using human intestinal epithelial Caco-2 cell monolayers grown in a transwell system, 3'-GL chemically synthesised from lactose was able to protect the intestinal barrier against breakdown of intestinal integrity, whereas alpha-3'-GL (with an α1-3 glycosidic linkage), 4'-GL, and 6'-GL (all chemically synthesized from lactose) demonstrated no significant results [110]. Previously, a commercial mixture of galacto-oligosaccharides also demonstrated a barrier-stabilising effect and resulted in improved integrity of the intestinal barrier function and reduced inflammatory response by using the same in vitro method [111].

Although these first pre-clinical data may indicate that certain galactosyllactoses, such as 3'-GL, have protective and immunomodulatory effects in the gut, more research is needed to further explore their role as HMOs.

Since 3'-GL in infant formula is a fermentation by-product, the safety of 3'-GL can be considered assured by the long history of safe use of the fermented formula in France [112]. The clinical evidence available on fermented infant formula is summarized in Section 3.5.3.

3.4. Synbiotics

Beneficial synergistic effects may be expected from a combination of probiotics and prebiotics, which are called synbiotics, using prebiotics to selectively increase abundance of both endogenous beneficial bacteria and beneficial microbes in the infant gut [113].

Given the evidence for an aberrant gut microbiota in infants with allergy [114,115] and the key role of the gut microbiota on immune system maturation [116], there is a strong rationale for developing a suitable pre- and probiotic (synbiotic) blend for use in infant formula for infants at high risk of allergy and infants with already developed allergy. A synbiotic mixture of prebiotics (scGOS/lcFOS or scFOS/lcFOS in a ratio of 9:1) and the probiotic strain Bifidobacterium breve M-16V already demonstrated promising results. This synbiotic combination compensated for delayed bifidobacteria colonisation in infants delivered by caesarean section (compared to vaginally delivered infants) in an exploratory, randomised, double-blind, controlled study with 153 infants with detection of total faecal bifidobacteria as primary study outcome [117]. Secondary outcomes demonstrated a lower proportion of potential pathogens (e.g., clostridia-related species) [118], lower faecal pH, and significant changes in SCFA pattern (e.g., higher acetate and lower butyric, isobutyric, and isovaleric acids) [119]. Furthermore, this synbiotic blend led to a significant decrease of SCORAD (Scoring Atopic Dermatitis) score in infants with atopic dermatitis (AD) and greater improvement of SCORAD score in infants with IgE (immunoglobulin E)-associated AD [119]. At the 1-year follow-up of this study, children with AD in the synbiotics group showed less asthma-like symptoms (frequent wheezing and wheezing and/or noisy breathing apart from colds) and asthma medication use [120].

However, even if some synbiotic combinations already display promising clinical results in infants, more randomised trials with longer follow-up are needed for the determination of their physiological and metabolic impact on the host [113].

3.5. Postbiotics

In contrast to probiotics, bacterial viability in postbiotics is not seen as an essential requirement for health benefits, providing a potential opportunity to foods that are not convenient for carrying viable bacteria [121], e.g., liquid infant formula.

In infant formulas, the concept of postbiotics is yet to be defined, although specific fermented infant formulas with postbiotics have been commercially available in Europe for decades. So far, most known postbiotics are derived from Lactobacillus and Bifidobacterium strains, which are also generally the most used probiotics [65].
3.5.1. Definition of Postbiotics

Recently, a provisional definition has been formulated that stipulates that postbiotics are compounds produced by microorganisms and released from food components or microbial constituents, including non-viable cells that, when administered in adequate amounts, promote health and well-being [65].

Examples of postbiotics have been summarised as follows [65]:

- Compounds deriving from bacterial metabolism, such as exopolysaccharides, vitamins, lactic acid, bacteriocins, enzymes, surfactants, antioxidants, and SCFAs.
- Complex molecules released from food compounds (enzymatically produced during food fermentation), such as peptides and galacto-oligosaccharides, e.g., 3'-GL and 6'-GL.
- Components released from lysed cells including DNA, RNA, cell walls and, perhaps, other cytoplasmic components, and surface layer proteins.

A consensus definition on postbiotics is currently being formulated by ISAPP [122].

3.5.2. Postbiotics through Fermentation

For many thousands of years, fermentation of food has been applied as a natural process to generate foods with particular properties, palatability, taste, and health benefits [113]. Most health benefits of fermented functional foods are accomplished by either the live microorganisms ingested or by postbiotics deriving from these microorganisms [65].

For cow’s milk-based infant formulas, fermentation processes typically use lactic acid-producing bacteria as a starter culture [65]. In addition to lactose consumption during fermentation, microbial enzymatic transgalactosylation can transform lactose into other lactose-based biomolecules, with 3'-GL as the major trisaccharide produced by *Streptococcus thermophilus* (e.g., *Streptococcus thermophilus* 065) from lactose fermentation [13]. The fermentation process is usually followed by physical treatment, which may include homogenisation, pasteurisation, sterilisation, and/or spray-drying [123].

Recently, a specific fermentation process has been developed for infant nutrition, using two specific types of food-grade lactic acid producing microorganisms (*Bifidobacterium breve* C50 and *Streptococcus thermophilus* 065) and naturally delivering postbiotics [12,124,125].

3.5.3. Benefits of Postbiotics in Infant Formula

In a mouse model, infant formula containing postbiotics deriving from a specific fermentation process combined with prebiotic scGOS/lcFOS (9:1) stimulated morphological (i.e., crypt villus length in ileum) and functional (i.e., ileal sucrase activity, gut permeability) gut maturation more similar to the mother-fed situation than infant formula without pre- or postbiotics [126]. Gut permeability measured by fluorescein isothiocyanate-dextran was similar in mice receiving post- and prebiotics and mother-fed mice, while it was significantly lower in mice receiving the control infant formula without post- or prebiotics (Figure 4). An early decrease in permeability, as observed in the control group, could have a lasting detrimental effect on health by changing immune maturation [127].
positive effects on gut function [128]. More recently, specific postbiotics deriving from fermentation have been derived according to the defined combination of the compounds. Cell structures, and metabolites with varying functionalities, and the benefits need to be established strain-specific as probiotics: each bacterial strain and each fermentation process generate unique cells, and the benefits cannot be attributed to any single metabolite alone.

Recently, an infant formula fermented by *Bifidobacterium breve* C50 and *Streptococcus thermophilus* 065—with and without prebiotic scGOS/lcFOS (9:1)—demonstrated its capacity to impact immune and gut health benefits in otherwise healthy infants (Table 2). Since fermented formulas may consist of a variety of bacterial metabolites, their benefits cannot be attributed to any single metabolite alone.

In a recent systematic review, limited evidence was demonstrated for specific postbiotics being recommended for treating paediatric diarrhoea and preventing common infectious diseases among children. For therapeutic trials, supplementation with heat-inactivated *Lactobacillus acidophilus* LB reduced the duration of diarrhoea, and for preventive trials, heat-inactivated *Lactobacillus paracasei* CBA L74 reduced the risk of diarrhoea, pharyngitis, and laryngitis [131].

In view of the suggested preclinical and clinical results, postbiotics should be considered as strain-specific as probiotics: each bacterial strain and each fermentation process generate unique cells, cell structures, and metabolites with varying functionalities, and the benefits need to be established according to the defined combination of the compounds.
Table 2. Impact of infant formula fermented with *Bifidobacterium breve* C50 and *Streptococcus thermophilus* 065 on immune and gut parameters.

| Infants                          | Duration (and Start) of Diet | Diet (No. of Infants) | Impact (Fermented vs. Standard Formula Group)                                                                 | Ref         |
|----------------------------------|------------------------------|------------------------|----------------------------------------------------------------------------------------------------------------|-------------|
|                                  |                              |                        | Higher faecal IgA response to polio vaccine                                                                   | [132]       |
| Healthy infants                  | 4 m (from birth)             | Fermented (11) vs. standard formula (9) | Reduced severity of acute diarrhoea (no effect on incidence and duration of diarrhoea episodes and number of hospital admissions) | [133]       |
| Healthy infants                  | 5 m (from 4–6 m of age)      | Fermented (464) vs. standard formula (449) | Enhanced thymus size (fermented formula group closer to HM)                                                  | [134]       |
| Healthy infants                  | 4 m (from birth)             | Fermented (30) vs. standard formula (30); HM (30) | Lower faecal calprotectin and higher secretory IgA (no effect on TNF-α)                                     | [135]       |
| Preterm infants (GA < 35 w)      | 2–5 w (from birth)           | Fermented (21) vs. standard formula (31) | Less positive SPT to cow’s milk (no effect on CMA incidence) and lower incidence of digestive and respiratory potentially allergic AEs | [136]       |
| Infants at high risk of atopy    | 12 m (from birth)            | Fermented (66) vs. standard formula (63) | No differences regarding parent-reported GI (and related) symptoms and investigator-reported AEs (except lower incidence of infantile colic) | [12]        |

**Impact on gut parameters**

(fermented formula \(^1\) additionally contained prebiotic scGOS/lcFOS (9:1))

| Infants                          | Diet (No. of Infants) | Impact (Fermented vs. Standard Formula Group)                                                                 | Ref         |
|----------------------------------|------------------------|----------------------------------------------------------------------------------------------------------------|-------------|
| Healthy infants                  | From 0–28 d until 17 w of life | Fermented (77) vs. standard formula (86); HM (90) | Softier stool consistency (fermented formula group closer to HM)                                              | [12]        |
|                                  |                        | Subset of 30 infants per study arm | No differences regarding parent-reported GI and related symptoms and investigator-reported AEs | [12]        |
|                                  |                        |                                  | except lower incidence of infantile colic                                                                    |             |
|                                  |                        |                                  | Stools: lower pH, higher levels of acetic acid and sIgA, increased *Bifidobacterium* sp, and decreased *Clostridium difficile* occurrence | [137]       |

\(^1\) Based on a recently developed fermentation process (Lactofidus\(^{TM}\)) generating bioactive compounds; one of these was 3'-GL at a level of ~250 µg/mL. Abbreviations: AE (adverse event), CMA (cow’s milk allergy), GA (gestational age), GI (gastrointestinal), HM (human milk), IgA (immunoglobulin A), SPT (skin prick test). Reference [137] is a congress abstract and is currently in preparation for full publication.
4. Conclusions

Breastfeeding is the natural and optimal way of feeding an infant. Current research still focuses on infant formula aiming to more closely resemble the composition and functionality of human milk, with some already comprising probiotics, prebiotics, synbiotics, and postbiotics. Human milk naturally provides these components by delivering HMOs (‘natural prebiotics’) and beneficial bacteria (‘natural probiotics’) and their metabolites (‘natural postbiotics’). In infant formula, these nutritional concepts are provided by different pre- and probiotic mixtures and a mixture of both (synbiotics) and, additionally, by using partly fermented infant formula with beneficial compounds produced by microorganisms that are released from food components or microbial constituents, including non-viable cells (postbiotics). One of the most current examples of such compounds is 3′-galactosyllactose (3′-GL), which is present in human milk and is a natural derivative of milk fermentation. Although such developments may pave the way for future infant formula alternatives for those infants who are not able to be (fully) breastfed, human milk feeding will always remain the unmatched goal for infant nutrition and development as well as provide many benefits for maternal health.

Author Contributions: S.S. and H.S. wrote, reviewed, and edited the manuscript. B.S. reviewed and edited the manuscript (in particular the biological aspects and health benefits of HMOs). G.V. reviewed and edited the manuscript (in particular the technological aspects of HMO production). All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: The authors are grateful to Jan Knol (Laboratory of Microbiology, Wageningen University, 6708 WE Wageningen, The Netherlands), Johan Garsen (Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3584 CA Utrecht, The Netherlands), and Marko Mank for their support and scientific expertise. All three are employees of Danone Nutricia Research, 3584 CT Utrecht, The Netherlands.

Conflicts of Interest: B.S. is employee of Danone Nutricia Research, which has proprietary rights to the prebiotic mixture of scGOS/lcFOS (9:1), mentioned in Section 3.2, and to the fermentation process Lactofidus™, mentioned in Section 3.5.2 and in Tables 1 and 2. All other authors declare no conflict of interest.

Abbreviations

2′-FL 2′-fucosyllactose
3′-GL 3′-galactosyllactose
4′-GL 4′-galactosyllactose
AD atopic dermatitis
AE adverse event
ATCC American Type Culture Collection
DFL difucosyllactose
DP degree of polymerisation
Caco adenocarcinoma of the colon
CBA chocolate blood agar
CFU colony forming units
CMA cow’s milk allergy
DNA deoxyribonucleic acid
DSM Dutch State Mines
EFSAs European Food Safety Authority
ESPGHAN European Society for Paediatric Gastroenterology, Hepatology and Nutrition
FDA U.S. Food & Drug Administration
FL fucosyllactoses
FOS fructo-oligosaccharides
FUT2 fucosyltransferase 2
GOS: galacto-oligosaccharides
GL: galactosyllactose
GRAS: generally recognized as safe
HM: human milk
HMO: human milk oligosaccharide
IF: infant formula
IgE: immunoglobulin E
ISAPP: International Scientific Association for Probiotics and Prebiotics
kDa: kilodalton
LA: Lactobacillus acidophilus
LB: lysogeny broth
LNnT: lacto-N-neotetraose
LNT: lacto-N-tetraose
NCDO: National Collection of Dairy Organism
NCIMB: National Collection of Industrial, Food and Marine Bacteria
NEC: necrotizing enterocolitis
QPS: qualitative presumption of safety
RNA: ribonucleic acid
SCORAD: scoring atopic dermatitis
scGOS/lcFOS (9:1): short-chain GOS/long-chain FOS (in a ratio of 9:1)
SCFA: short-chain fatty acid
SEM: standard error of the mean
SL: sialyllactose
spp: subspecies

References

1. Thurow, R. The First 1,000 Days: A Crucial Time for Mothers and Children—And the World. *Breastfeed. Med.* 2016, 11, 416–418. [CrossRef]
2. Victora, C.G.; Bahl, R.; Barros, A.J.D.; A França, G.V.; Horton, S.; Krasevec, J.; Murch, S.; Sankar, M.J.; Walker, N.; Rollins, N.C. Breastfeeding in the 21st century: Epidemiology, mechanisms, and lifelong effect. *Lancet* 2016, 387, 475–490. [CrossRef]
3. Bischoff, S.C. ‘Gut health’: A new objective in medicine? *BMC Med.* 2011, 9, 24. [CrossRef] [PubMed]
4. Martin, R.; Nauta, A.J.; Ben Amor, K.; Knippels, L.M.; Knol, J.; Garssen, J. Early life: Gut microbiota and immune development in infancy. *Benef. Microbes* 2010, 1, 367–382. [CrossRef] [PubMed]
5. Dzidic, M.; Boix-Amorós, A.; Selma-Royo, M.; Mira, A.; Collado, M.C. Gut Microbiota and Mucosal Immunity in the Neonate. *Med. Sci.* 2018, 6, 56. [CrossRef]
6. Collado, M.C.; Cernada, M.; Baüerl, C.; Vento, M.; Pérez-Martínez, G. Microbial ecology and host-microbiota interactions during early life stages. *Gut Microbes* 2012, 3, 352–365. [CrossRef]
7. Oozeer, R.; Rescigno, M.; Ross, R.P.; Knol, J.; Blaut, M.; Khlebnikov, A.; Dore, J. Gut health: Predictive biomarkers for preventive medicine and development of functional foods. *Br. J. Nutr.* 2010, 103, 1539–1544. [CrossRef]
8. Goehring, K.C.; Marriage, B.J.; Oliver, J.S.; A Wilder, J.; Barrett, E.G.; Buck, R.H. Similar to Those Who Are Breastfed, Infants Fed a Formula Containing 2′-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial. *J. Nutr.* 2016, 146, 2559–2566. [CrossRef] [PubMed]
9. Marriage, B.J.; Buck, R.H.; Goehring, K.C.; Oliver, J.S.; Williams, J.A. Infants Fed a Lower Calorie Formula With 2′FL Show Growth and 2′FL Uptake Like Breast-Fed Infants. *J. Pediatr. Gastroenterol. Nutr.* 2015, 61, 649–658. [CrossRef]
10. Reverri, E.J.; Devitt, A.A.; Kajzer, J.A.; Baggs, G.; Borschel, M.W. Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose. *Nutrients* 2018, 10, 1346. [CrossRef]
11. Puccio, G.; Alliet, P.; Cajozzo, C.; Janssens, E.; Corsello, G.; Sprenger, N.; Wernimont, S.; Egli, D.; Gosoniu, L.; Steenhout, P. Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial. *J. Pediatr. Gastroenterol. Nutr.* 2017, 64, 624–631. [CrossRef] [PubMed]
12. Rodríguez-Herrera, A.; Mulder, K.; Bouritius, H.; Rubio, R.; Muñoz-Hoyos, A.; Agosti, M.; Lista, G.; Corviglia, L.; Ludwig, T.; Abrahamse-Berkeveeld, M.; et al. Gastrointestinal Tolerance, Growth and Safety of a Partly Fermented Formula with Specific Prebiotics in Healthy Infants: A Double-Blind, Randomized, Controlled Trial. *Nutrients* 2019, 11, 1530. [CrossRef] [PubMed]

13. Perrin, V.; Fenet, B.; Praly, J.-P.; Lecroix, F.; Ta, C.D. Identification and synthesis of a trisaccharide produced from lactose by transgalactosylation. *Carbohydr. Res.* 2000, 325, 202–210. [CrossRef]

14. Ayechu-Muruzabal, V.; Van Stigt, A.H.; Mank, M.; Willemsen, L.E.M.; Stahl, B.; Garssen, J.; Land, B.V. Diversity of Human Milk Oligosaccharides and Effects on Early Life Immune Development. *Front. Pediatr.* 2018, 6, 239. [CrossRef]

15. Bergmann, H.; Rodríguez, J.M.; Salminen, S.; Szajewska, H. Probiotics in human milk and probiotic supplementation in infant nutrition: A workshop report. *Br. J. Nutr.* 2014, 112, 1119–1128. [CrossRef]

16. Engfer, M.B.; Stahl, B.; Finke, B.; Sawatzki, G.; Daniel, H. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. *Am. J. Physiol. Endocrinol. Metab.* 2019, 316, E347–E357. [CrossRef] [PubMed]

17. Fernández, L.; Langa, S.; Martin, V.; Jiménez, E., Martin, R.; Rodríguez, J.M. The microbvia of human milk in healthy women. *Cell. Mol. Biol.* 2013, 59, 31–42.

18. Andreas, N.J.; Kampmann, B.; Le Doare, K. Human breast milk: A review on its composition and bioactivity. *Early Hum. Dev.* 2015, 91, 629–635. [CrossRef]

19. Wegh, C.A.; Geerlings, S.Y.; Knol, J.; Roeselers, G.; Belzer, C. Postbiotics and Their Potential Applications in Early Life Nutrition and Beyond. *Int. J. Mol. Sci.* 2019, 20, 4673. [CrossRef]

20. Aakko, J.; Kumar, H.; Rautava, S.; Wise, A.; Aturan, C.; Bode, L.; Isolauri, E.; Salminen, S. Human milk oligosaccharide categories define the microbiota composition in human colostrum. *Benef. Microbes* 2017, 8, 563–567. [CrossRef]

21. Wise, A.; Robertson, B.; Choudhury, B.; Rautava, S.; Isolauri, E.; Salminen, S.; Bode, L. Infants Are Exposed to Human Milk Oligosaccharides Already in utero. *Front. Pediatr.* 2018, 6, 270. [CrossRef] [PubMed]

22. Hirschmugl, B.; Brandl, W.; Csapo, B.; Van Poppel, M.N.M.; Köfeler, H.C.; Desoye, G.; Wadsack, C.; Jantscher-Krenn, E. Evidence of Human Milk Oligosaccharides in Cord Blood and Maternal-to-Fetal Transport across the Placenta. *Nutrients* 2019, 11, 2640. [CrossRef]

23. Jantscher-Krenn, E.; Aigner, J.; Reiter, B.; Köfeler, H.C.; Csapo, B.; Desoye, G.; Bode, L.; Van Poppel, M.N.M. Evidence of human milk oligosaccharides in maternal circulation already during pregnancy: A pilot study. *Am. J. Physiol. Endocrinol. Metab.* 2019, 316, E347–E357. [CrossRef] [PubMed]

24. Thurl, S.; Henker, J.; Siegel, M.; Tovar, K.; Sawatzki, G. Detection of four human milk groups with respect to Lewis blood group dependent oligosaccharides. *Glycoconj. J.* 1997, 14, 795–799. [CrossRef] [PubMed]

25. Thurl, S.; Munzert, M.; Boehm, G.; Matthews, C.; Stahl, B. Systematic review of the concentrations of oligosaccharides in human milk. *Nutr. Rev.* 2017, 75, 920–933. [CrossRef] [PubMed]

26. Urashima, T.; Hirabayashi, J.; Sato, S.; Kobata, A. Human Milk Oligosaccharides as Essential Tools for Basic and Application Studies on Galectins. *Trends Glycosci. Glycotechnol.* 2018, 30, SJ11–SJ24. [CrossRef]

27. Bode, L. Human milk oligosaccharides: Every baby needs a sugar mma. *Glycobiology* 2012, 22, 1147–1162. [CrossRef]

28. Walker, W.A.; Iyengar, R.S. Breast milk, microbiota, and intestinal immune homeostasis. *Pediatr. Res.* 2014, 77, 220–228. [CrossRef]

29. Bode, L.; Kunz, C.; Muhly-Reinholz, M.; Mayer, K.; Seeger, W.; Rudloff, S. Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk oligosaccharides. *Thromb. Haemost.* 2004, 92, 1402–1410. [CrossRef]

30. Eiwegger, T.; Stahl, B.; Haidl, P.; Schmitt, J.; Boehm, G.; Dehlink, E.; Urbanek, R.; Szépfalusí, Z. Prebiotic oligosaccharides: In vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. *Pediatr. Allergy Immunol.* 2010, 21, 1179–1188. [CrossRef]

31. Eiwegger, T.; Stahl, B.; Schmitt, J.; Boehm, G.; Gerstmayr, M.; Pichler, J.; Dehlink, E.; Loibichler, C.; Urbanek, R.; Szepfalusi, Z.; et al. Human Milk–Derived Oligosaccharides and Plant-Derived Oligosaccharides Stimulate Cytokine Production of Cord Blood T-Cells In Vitro. *Pediatr. Res.* 2004, 56, 536–540. [CrossRef] [PubMed]

32. Xiao, L.; Engen, P.; Leusink-Muis, T.; Van Ark, I.; Stahl, B.; A Overbeek, S.; Garssen, J.; Naqib, A.; Green, S.J.; Keshavarzian, A.; et al. The Combination of 2′′-Fucosyllactose with Short-Chain Galacto-Oligosaccharides and Long-Chain Fructo-Oligosaccharides that Enhance Influenza Vaccine Responses Is Associated with Mucosal Immune Regulation in Mice. *J. Nutr.* 2019, 149, 856–869. [CrossRef] [PubMed]
33. Newburg, D.S.; Ruiz-Palacios, G.M.; Altaye, M.; Chaturvedi, P.; Meinzen-Derr, J.; Guerrero, M.D.L.; Morrow, A.L. Innate protection conferred by fucosylated oligosaccharides of human milk against diarrhea in breastfed infants. *Glycobiology* 2003, 14, 253–263. [CrossRef] [PubMed]

34. Wang, S.; Harvey, L.; Martin, R.; Van Der Beek, E.M.; Knol, J.; Cryan, J.F.; Renes, I. Targeting the gut microbiota to influence brain development and function in early life. *Neurosci. Biobehav. Rev.* 2018, 95, 191–201. [CrossRef] [PubMed]

35. Cheng, L.; Akkerman, R.; Kong, C.; Walvoort, M.T.C.; De Vos, P. More than sugar in the milk: Human milk oligosaccharides as essential bioactive molecules in breast milk and current insight in beneficial effects. *Crit. Rev. Food Sci. Nutr.* 2020, 1–17. [CrossRef] [PubMed]

36. Urashima, T.; Asakuma, S.; Leo, F.; Fukuda, K.; Messer, M.; Oftedal, O.T. The Predominance of Type I Oligosaccharides Is a Feature Specific to Human Breast Milk. *Adv. Nutr.* 2012, 3, 473–4825. [CrossRef] [PubMed]

37. Kobata, A. Structures and functions of the sugar chains of glycoproteins. *JBIC J. Biol. Inorg. Chem.* 1992, 209, 483–501. [CrossRef]

38. Newburg, D.; Ko, J.S.; Leone, S.; Nanthakumar, N.N. Human Milk Oligosaccharides and Synthetic Galactosyloligosaccharides Contain 3′-, 4-, and 6′-Galactosyllactose and Attenuate Inflammation in Human T84, NCM-460, and H4 Cells and Intestinal Tissue Ex Vivo. *J. Nutr.* 2015, 146, 358–367. [CrossRef]

39. Sumiyoshi, W.; Urashima, T.; Nakamura, T.; Arai, I.; Nagasawa, T.; Saito, T.; Tsumura, N.; Wang, B.; Brand-Miller, J.; Watanabe, Y.; et al. Galactosyllactoses in the Milk of Japanese Women: Changes in Concentration during the Course of Lactation. *J. Appl. Glycosci.* 2004, 51, 341–344. [CrossRef]

40. Donald, A.S.; Feeney, J. Separation of human milk oligosaccharides by recycling chromatography. First isolation of lacto-N-neo-difucohexaose II and 3′-galactosyllactose from this source. *Carbohydr. Res.* 1988, 178, 79–91. [CrossRef]

41. Gänzle, M.G.; Haase, G.; Jelen, P. Lactose: Crystallization, hydrolysis and value-added derivatives. *Int. Dairy J.* 2008, 18, 685–694. [CrossRef]

42. Sugawara, M.; Idota, T. A new oligosaccharide: 4′-galactosyllactose in human milk. In *Proceedings of the Annual Meeting of Japan Society for Bioscience, Biotechnology, and Agrochemistry, Tokyo, Japan*, 3 August 1995; p. 132.

43. Yamashita, K.; Kobata, A. Oligosaccharides of human milk. Isolation and characterization of a new trisaccharide, 6′-galactosyllactose. *Arch. Biochem. Biophys.* 1974, 174, 582–591. [CrossRef]

44. Mank, M.; Blijenberg, B.; Stahl, B. Label free targeted LC-ESI-MS2 analysis of 3′- and 6′-galactosyllactose in human milk with enhanced structural selectivity. *J. Pediatr. Gastroenterol. Nutr.* 2019, 68, N-P-126.

45. Coppa, G.; Pierani, P.; Zampini, L.; Carloni, I.; Carlucci, A.; Gabrielli, O. Oligosaccharides in human milk during different phases of lactation. *Acta Paediatr.* 1999, 88, 89–94. [CrossRef]

46. Austin, S.; De Castro, C.A.; Sprenger, N.; Affolter, M.; Affolter, M.; Garcia-Rodenas, C.L.; Beuport, L.; Tolsa, J.-F.; Fumeaux, C. J.F. Human Milk Oligosaccharides in the Milk of Mothers Delivering Term versus Preterm Infants. *Nutrients* 2019, 11, 1282. [CrossRef] [PubMed]

47. Thurl, S.; Munzert, M.; Henker, J.; Boehm, G.; Müller-Werner, B.; Jelinek, J.; Stahl, B. Variation of human milk oligosaccharides in relation to milk groups and lactational periods. *Br. J. Nutr.* 2010, 104, 1261–1271. [CrossRef] [PubMed]

48. Urashima, T.; Kitaoka, M.; Terabayashi, T.; Fukuda, K.; Ohnishi, M.; Kobata, A. Milk oligosaccharides. In *Oligosaccharides: Sources, Properties and Applications*; Gordon, N.S., Ed.; Nova Science Publishers: Hauppauge, NY, USA, 2011.

49. Van De Wiele, T.; Boon, N.; Possemiers, S.; Jacobs, H.; Verstraete, W. Inulin-type fructans of longer degree of polymerization exert more pronounced in vitro prebiotic effects. *J. Appl. Microbiol.* 2007, 102, 452–460. [CrossRef]
52. Jeurink, P.; Van Bergenhenegouwen, J.; Jiménez, E.; Knippels, L.; Fernández, L.; Garssen, J.; Knol, J.; Rodríguez, J.M.; Martin, R. Human milk: A source of more life than we imagine. *Benef. Microbes* 2013, 4, 17–30. [CrossRef]

53. Witkowska-Zimny, M.; Kaminska-El-Hassan, E. Cells of human breast milk. *Cell. Mol. Biol. Lett.* 2017, 22, 11. [CrossRef]

54. Reyman, M.; Van Houten, M.A.; Van Baarle, D.; Bosch, A.A.T.M.; Man, W.H.; Chu, M.L.J.N.; Arp, K.; Watson, R.L.; Sanders, E.A.M.; Fuentes, S.; et al. Impact of delivery mode-associated gut microbiota dynamics on health in the first year of life. *Nat. Commun.* 2019, 10, 4997. [CrossRef] [PubMed]

55. Underwood, M.A.; German, J.B.; Lebrilla, C.B.; Mills, D.A. Bifidobacterium longum subspecies infantis: Champion colonizer of the infant gut. *Pediatr. Res.* 2014, 77, 229–235. [CrossRef]

56. Thai, J.D.; Gregory, K.E. Bioactive Factors in Human Breast Milk Attenuate Intestinal Inflammation during Early Life. *Nutrients* 2020, 12, 581. [CrossRef] [PubMed]

57. Lackey, K.A.; Williams, J.E.; Meehan, C.L.; Zacheck, J.A.; Benda, E.D.; Price, W.J.; Foster, J.A.; Sellen, D.W.; Kamau-Mbuthia, E.W.; Kamundia, E.W.; et al. What’s Normal? Microbiomes in Human Milk and Infant Feces Are Related to Each Other but Vary Geographically: The INSPIRE Study. *Front. Nutr.* 2019, 6, 45. [CrossRef] [PubMed]

58. Rodríguez, J.M. The origin of human milk bacteria: Is there a bacterial entero-mammary pathway during late pregnancy and lactation? *Adv. Nutr.* 2014, 5, 779–784. [CrossRef]

59. Pärnänen, K.M.M.; Karkman, A.; Hultman, J.; Lyra, C.; Bengtsson-Palme, J.; Larsson, D.G.J.; Rautava, S.; Isolauri, E.; Salminen, S.; Kumar, H.; et al. Maternal gut and breast milk microbiota affect infant gut antibiotic resistome and mobile genetic elements. *Nat. Commun.* 2018, 9, 3891. [CrossRef]

60. Boix-Amorós, A.; Collado, M.C.; Mira, A. Relationship between Milk Microbiota, Bacterial Load, Macronutrients, and Human Cells during Lactation. *Front. Microbiol.* 2016, 7, 3389. [CrossRef]

61. Heikkila, M.; Saris, P.E.J. Inhibition of Staphylococcus aureus by the commensal bacteria of human milk. *J. Appl. Microbiol.* 2003, 95, 471–478. [CrossRef]

62. Gueimonde, M.; Laitinen, K.; Salminen, S.; Isolauri, E. Breast Milk: A Source of Bifidobacteria for Infant Gut Development and Maturation? *Neonatology* 2007, 92, 64–66. [CrossRef]

63. Bardanzellu, F.; Fanos, V.; Strigini, F.A.L.; Artini, P.G.; Peroni, D.G. Human Breast Milk: Exploring the Linking Ring Among Emerging Components. *Front. Pediatr.* 2018, 6. [CrossRef] [PubMed]

64. Gómez-Gallego, C.; Morales, J.M.; Monleon, D.; Du Toit, E.; Kumar, H.; Linderborg, K.M.; Zhang, Y.; Yang, B.; Isolauri, E.; Salminen, S.; et al. Human Breast Milk NMR Metabolomic Profile across Specific Geographical Locations and Its Association with the Milk Microbiota. *Nutrients* 2018, 10, 1355. [CrossRef] [PubMed]

65. Collado, M.; Vinderola, G.; Salminen, S. Postbiotics: Facts and open questions. A position paper on the need for a consensus definition. *Benef. Microbes* 2019, 10, 711–719. [CrossRef] [PubMed]

66. Moossavi, S.; Sepehri, S.; Robertson, B.; Bode, L.; Goruk, S.; Field, C.J.; Lix, L.M.; De Souza, R.J.; Becker, A.B.; Swanson, K.S.; Cani, P.D.; et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat. Rev. Gastroenterol. Hepatol.* 2017, 14, 491–502. [CrossRef]

67. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of probiotics. *Nat. Rev. Gastroenterol. Hepatol.* 2017, 14, 491–502. [CrossRef]

68. De Vrese, M.; Schrezenmeir, J. Probiotics, Prebiotics, and Synbiotics. *Plant Cells* 2008, 111, 1–66. [CrossRef]

69. Salminen, S.; Szajewska, H.; Knol, J. *The Biotics Family in Early Life*; John Wiley and Sons Ltd.: Chichester, UK, 2019.
73. O’Toole, P.W.; Marchesi, J.R.; Hill, C. Next-generation probiotics: The spectrum from probiotics to live biotherapeutics. *Nat. Microbiol.* 2017, 2, 17057. [CrossRef]

74. Braegger, C.; Chmielewska, A.; Decsi, T.; Kolaček, S.; Mihatsch, W.; Moreno, L.; Pieścik, M.; Puntis, J.; Shamir, R.; Szajewska, H.; et al. Supplementation of Infant Formula With Probiotics and/or Prebiotics: A Systematic Review and Comment by the ESPGHAN Committee on Nutrition. *J. Pediatr. Gastroenterol. Nutr.* 2011, 52, 238–250. [CrossRef]

75. Thurl, S.; Henker, J.; Taut, H.; Tovar, K.; Sawatzki, G. Variations of neutral oligosaccharides and lactose in human milk during the feeding. *Eur. J. Nutr.* 2017, 58, 164–176. [CrossRef] [PubMed]

76. Ombrello, S.; Rudlo, S.; Moro, G. Structural and Functional Aspects of Prebiotics Used in Infant Nutrition. *J. Nutr.* 2008, 138, 1818S–1828S. [CrossRef] [PubMed]

77. Moro, G.; Boehm, G. Clinical Outcomes of Prebiotic Intervention Trials during Infancy: A Review. *Funct. Food Rev.* 2012, 4, 101–113. [CrossRef]

83. Thurl, S.; O.; Moro, G. Determination of neutral oligosaccharide fractions from human milk by gel permeation chromatography. *J. Chromatogr. B Biomed. Sci. Appl.* 1991, 568, 291–300. [CrossRef]

84. Bych, K.; Mikš-Krajnik, M.; Johanson, T.; Hederos, M.J.; Vigsnaes, L.K.; Becker, P. Production of HMOs using microbial hosts—From cell engineering to large scale production. *Curr. Opin. Biotechnol.* 2019, 56, 130–137. [CrossRef]

85. Vandenplas, Y.; Berger, B.; Carnielli, V.P.; Książyk, J.; Lagström, H.; Sánchez-Luna, M.; Migacheva, N.; Miqdady, M.; Al Mistarihi, J.; Azaz, A.; Rawat, D. Prebiotics in the Infant Microbiome: The Past, Present, and Future. *Pediatr. Gastroenterol. Hepatol. Nutr.* 2020, 23, 1–14. [CrossRef] [PubMed]

86. Walsh, C.; Lane, J.A.; Van Sinderen, D.; Hickey, R.M. From lab bench to formulated ingredient: Strategies for Improved Enzymatic Transglycosylation. *Molecules* 2019, 24, 2033. [CrossRef]

87. C.C.; Albermann, C. Production of human milk oligosaccharides by enzymatic and whole-cell microbial biotransformations. *J. Biotechnol.* 2017, 258, 79–91. [CrossRef]

88. Vandenplas, Y.; Berger, B.; Carnielli, V.P.; Książyk, J.; Lagström, H.; Sánchez-Luna, M.; Migacheva, N.; Miqdady, M.; Al Mistarihi, J.; Azaz, A.; Rawat, D. Prebiotics in the Infant Microbiome: The Past, Present, and Future. *Pediatr. Gastroenterol. Hepatol. Nutr.* 2020, 23, 1–14. [CrossRef] [PubMed]

89. Feber, C.; Albermann, C. Construction of Escherichia coli strains with chromosomally integrated expression cassettes for the synthesis of 2′-fucosyllactose. *Microb. Cell Factories* 2013, 12, 40. [CrossRef] [PubMed]

90. Baumgärtner, F.; Conrad, J.; Sprenger, G.A.; Albermann, C. Synthesis of the Human Milk Oligosaccharide Lacto-N-Tetraose in Metabolically Engineered Plasmid-Free *E. coli*. *ChemBioChem* 2014, 15, 1896–1900. [CrossRef]

91. Baumgärtner, F.; Seitz, L.; Sprenger, G.A.; Albermann, C. Production of human milk oligosaccharides by enzymatic and whole-cell microbial biotransformations. *J. Biotechnol.* 2017, 258, 79–91. [CrossRef]
133. Thibault, H.; Aubert-Jacquin, C.; Goulet, O. Effects of Long-term Consumption of a Fermented Infant Formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on Acute Diarrhea in Healthy Infants. *J. Pediatr. Gastroenterol. Nutr.* **2004**, *39*, 147–152. [CrossRef] [PubMed]

134. Indrio, F.; Ladisa, G.; Mautone, A.; Montagna, O. Effect of a Fermented Formula on Thymus Size and Stool pH in Healthy Term Infants. *Pediatr. Res.* **2007**, *62*, 98–100. [CrossRef] [PubMed]

135. Campeotto, F.; Suau, A.; Kapel, N.; Magne, F.; Viallon, V.; Ferraris, L.; Waligora-Dupriet, A.-J.; Soulaines, P.; Leroux, B.; Kalach, N.; et al. A fermented formula in pre-term infants: Clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA. *Br. J. Nutr.* **2011**, *105*, 1843–1851. [CrossRef]

136. Morisset, M.; Aubert-Jacquin, C.; Soulaines, P.; Moneret-Vautrin, D.-A.; Dupont, C. A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy. *Eur. J. Clin. Nutr.* **2010**, *65*, 175–183. [CrossRef] [PubMed]

137. Tims, S.; Roeselers, G.; Knol, K. Gut Microbiota Composition Modulation by Partly Fermented Infant Formulae Supplemented with Prebiotics, scGOS/lcFOS. *J. Pediatr. Gastroenterol. Nutr.* **2018**, *66*, N-eP-029.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).